HIV, or Human Immunodeficiency Virus, is a significant global health concern, including in Kenya. According to the Kenya AIDS Strategic Plan 2018-2023, approximately 1.1 million people were living with HIV in 2018. Early detection and effective treatment are crucial to manage HIV and prevent its progression to AIDS. This article delves into the HIV treatment guidelines in Kenya, focusing on antiretroviral therapy (ART) and other supportive care.

Kenya's HIV treatment guidelines are aligned with World Health Organization (WHO) recommendations and are updated regularly to reflect the latest scientific evidence. The Ministry of Health, Kenya, is responsible for developing and implementing these guidelines, ensuring that people living with HIV have access to quality care.

Antiretroviral Therapy (ART)
ART is the use of medications to treat HIV infection. The primary goal of ART is to suppress viral load to undetectable levels, improve immune function, and reduce HIV-related morbidity and mortality. In Kenya, ART is provided free of charge through the government's HIV treatment program.

ART initiation in Kenya is recommended for all adults and adolescents (10 years and above) with HIV, regardless of CD4 count. Children under 10 years are initiated on ART if they have severe or advanced HIV disease, or if they are under 1 year old.
First-Line ART Regimen

Kenya's current first-line ART regimen for adults and adolescents is Tenofovir Disoproxil Fumarate (TDF) + Lamivudine (3TC) + Efavirenz (EFV) or Nevirapine (NVP). For children, the first-line regimen varies based on age and weight, typically including TDF, 3TC, and either EFV or NVP.
First-line ART regimens are effective and well-tolerated, with high rates of viral suppression and immune recovery. However, drug resistance can develop if ART is not taken consistently. Therefore, adherence support is a critical component of HIV care in Kenya.
Second-Line and Third-Line ART Regimens

If a person experiences treatment failure on the first-line regimen, a second-line regimen is initiated. The current second-line regimen in Kenya is Zidovudine (AZT) + Didanosine (ddI) + Lopinavir/Ritonavir (LPV/r). If there is further treatment failure, a third-line regimen is considered, which may include drugs like Tenofovir Alafenamide (TAF), Darunavir (DRV), and Rilpivirine (RPV).
Second-line and third-line regimens are more complex, have a higher pill burden, and are more expensive than first-line regimens. Therefore, preventing treatment failure is a key focus of HIV care in Kenya.
Supportive Care and Monitoring

ART is just one component of comprehensive HIV care. Other aspects of care, such as tuberculosis (TB) screening, management of opportunistic infections, and prevention of HIV-related complications, are equally important. Regular clinical and laboratory monitoring is also crucial to assess response to ART and adjust treatment as needed.
Kenya's HIV treatment guidelines emphasize the importance of a holistic approach to HIV care, involving not only medical treatment but also psychosocial support, nutrition, and prevention of HIV transmission to others (treatment as prevention).




















Tuberculosis Screening and Management
TB is a common opportunistic infection in people living with HIV. Kenya's HIV treatment guidelines recommend TB screening at ART initiation and every 6 months thereafter. If TB is diagnosed, it is managed according to Kenya's TB treatment guidelines, with ART initiated as early as possible during TB treatment.
TB/HIV co-infection is a significant challenge in Kenya, but with integrated TB/HIV services, it is possible to effectively manage both conditions and improve outcomes for people living with HIV.
Prevention of Mother-to-Child Transmission (PMTCT)
PMTCT is a key strategy to reduce new HIV infections in Kenya. Women living with HIV who become pregnant are initiated on ART as early as possible, regardless of CD4 count. Infant prophylaxis with antiretrovirals is also provided to prevent HIV transmission from mother to child.
PMTCT services are integrated with maternal and child health services in Kenya, ensuring that pregnant women and their infants receive comprehensive care to prevent HIV transmission and improve health outcomes.
In Kenya, HIV treatment has evolved significantly over the years, with ART now available to all who need it. However, there is still work to be done to ensure that everyone living with HIV knows their status, initiates ART early, and remains on treatment consistently. By working together, we can end AIDS in Kenya and beyond.